

B S R & Co. LLP

Chartered Accountants

Unit No# 502, 5th Floor, Tower- B,
Plot # 07 Advant Navis Business Park
Sector- 142, Noida Expressway
Noida - 201305, UP, (India)
Tel: +91 120 682 9700
Fax: +91 120 682 9999

Limited Review Report on unaudited standalone financial results of Jubilant Pharmova Limited for the quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Jubilant Pharmova Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Jubilant Pharmova Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2023 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it



B S R & Co. LLP

Limited Review Report (Continued)
Jubilant Pharmova Limited

contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



Manish Gupta

Partner

Noida

19 July 2023

Membership No.: 095037

UDIN: 23095037BGYZHF4174

Jubilant Pharmova Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24116UP1978PLC004624

Website: www.jubilantpharmova.com, Email: investors@jubl.com, Tel: +91-5924-267437


Statement of Standalone Unaudited Financial Results for the Quarter ended 30 June 2023

(₹ in million)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2023	2023	2022	2023
1	Revenue from operations				
	a) Sales/Income from operations	2,039	1,894	2,000	7,744
	b) Other operating income	135	104	46	357
	Total revenue from operations	2,174	1,998	2,046	8,101
2	Other income	159	137	102	1,379
3	Total income (1+2)	2,333	2,135	2,148	9,480
4	Expenses				
	a) Cost of materials consumed	719	904	883	3,963
	b) Purchases of stock-in-trade	26	(23)	9	148
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	312	126	240	35
	d) Employee benefits expense	475	401	406	1,673
	e) Finance costs	64	57	32	185
	f) Depreciation and amortization expense	114	113	92	432
	g) Other expenses	600	569	551	2,251
	Total expenses	2,310	2,147	2,213	8,687
5	Profit/(loss) before exceptional items and tax (3-4)	23	(12)	(65)	793
6	Exceptional items	-	-	-	-
7	Profit/(loss) before tax (5-6)	23	(12)	(65)	793
8	Tax expense/(credit)				
	- Current tax	4	(6)	-	138
	- Deferred tax charge/(credit)	-	302	(13)	156
	Total tax expense/(credit)	4	296	(13)	294
9	Net profit/(loss) for the period (7-8)	19	(308)	(52)	499
10	Other comprehensive (loss)/income				
	i) a) Items that will not be reclassified to profit or loss	(3)	-	3	9
	b) Income tax relating to items that will not be reclassified to profit or loss	1	7	(1)	4
	ii) a) Items that will be reclassified to profit or loss	-	-	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Other comprehensive (loss)/income for the period	(2)	7	2	13
11	Total comprehensive income/(loss) for the period (9+10)	17	(301)	(50)	512
12	Earnings per share of ₹ 1 each (not annualized)				
	Basic (₹)	0.12	(1.94)	(0.33)	3.13
	Diluted (₹)	0.12	(1.94)	(0.33)	3.13
13	Paid-up equity share capital (face value per share ₹ 1)	159	159	159	159
14	Reserves excluding revaluation reserves (other equity)				23,986
	See accompanying notes to the Standalone Unaudited Financial Results				

1. In accordance with Ind AS 108 "Operating Segments", segment information has been provided in the consolidated financial results of the Group and therefore no separate disclosure on segment information is given in these standalone financial results.
2. The figures for the preceding quarter ended 31 March 2023, as reported in these standalone financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to date figures until the end of third quarter of that financial year. Also, the figures until the end of the third quarter had only been reviewed and not subjected to audit. Further, previous period figures have been regrouped / reclassified to conform to the current period's classification.
3. The above standalone unaudited financial results were subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 19 July 2023. The review report of the Statutory Auditors is being filed with BSE Limited and National Stock Exchange of India Limited. For more details on standalone unaudited results, visit Investors' section of our website at www.jubilantpharmova.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Pharmova Limited



Priyavrat Bhartia
Managing Director

Place : Noida
Date : 19 July 2023